Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience. Affecting more than 21 million people globally, DME ...

Biotechnology company Nanoscope Therapeutics recently announced the formation of Vision Advisory Committee (VAC). 1 VAC is “a group of renowned experts in retina treatment and commercialization,” a ...

Clinical-stage biotechnology company PYC Therapeutics recently held a type B meeting with the US Food and Drug Administration (FDA) to discuss requirements for a new drug application (NDA) for the ...

Christine Kay, MD, presented interim 1-year data from a phase 1/2 study of an investigational gene therapy (OPGx-LCA5; Opus Genetics) for LCA5-related Leber congenital amaurosis at the Clinical Trials ...

Retina specialist Jay Chhablani, MD, discusses 3D choroidal vessel segmentation, uncovering critical insights into macular degeneration, diabetic retinopathy, and potential systemic disease ...

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic ...

A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need ...

The phase 2/3 clinical trial for OCU410ST will enroll 51 participants diagnosed with Stargardt disease. In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked ...

Christina Weng, MD, spoke with us about her presentation on the emerging technology of home OCT and its role in AMD. She gave this presentation at Clinical Trials at the Summit meeting being held in ...

Aviceda Therapeutics has completed enrollment of the phase 2b trial of the SIGLEC Study. The study will assess the safety and efficacy of AVD-104, the company’s formulation designed to treat ...

Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

Michael Singer, MD, presented 100-week results from the RESTORE trial and shares key takeaways from his presentation at this year's American Society of Retina Specialists (ASRS) meeting. Video ...